Major League Baseball recently released a report about pitcher injuries. It was the culmination of interviews with 200 subject-matter experts about the growing rash of arm troubles in the sport ...

B. Riley has initiated Foghorn Therapeutics (NASDAQ:FHTX) at buy citing the company's development of SMARCA2 inhibitors to fight tumors. The investment bank has a $10 price target (~151% upside ...